• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Human Genome Sciences

Related Topics

  1. American Exploration
  2. Lime Energy
  3. Zoran Corporation
  4. Blue Rhino
  5. Bankers Trust
  6. iShares S&P North Amer Technology

Popular Topics

  1. Eagle Bulk Shipping
  2. Commercial Banks
  3. Emerging Markets
  4. European Union
  5. Interest Rate

Human Genome Sciences

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  5. Research
  1. Human Genome Sciences HGSI Q4 2011 Earnings Call Transcript

    Good day everyone and welcome to the Human Genome Sciences' Fourth Quarter 2011 and Full Year Financial Results Webcast. Today's webcast is being recorded. At this time, I will turn things over to Mr. Thomas Watkins. Please go ahead Mr. Watkins.

  2. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  3. Top Biotech Acquisition Candidates

    2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.

  4. Health-Care Investing Alive and Well

    Two veteran investors discuss the winners and losers of reform and where they're looking for future growth.

  5. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

  6. The Market's Most Overvalued Stocks

    Equity valuations as a whole have barely budged in 2005, but the market remains a bit on the pricey side when comparing to Morningstar's collective fair value estimates (To see more on Morningstar's perspective on market valuations, check out our Market Valuation Graph ). The median stock in our ...

  7. M&A Just Beginning

    Health care, energy, and tech--where the big companies have the cash, and the mid- and small companies have a lot of growth--are ripe for continued M&A activity, says Legg Mason ClearBridge's Evan Bauman.

  8. No Sign of Slowdown in Biotech M&A

    High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.

  9. Our Top Five Biotech Acquisition Candidates

    M&A activity grew in 2010, and we expect deal volume to remain strong in 2011.

Our Products
Tools
Resources
Services
Upcoming Events
Conferences
Webinars

©2012 Morningstar Advisor. All right reserved.